Heartflow, Inc. (HTFL) Company Overview

What does Heartflow do?

Heartflow, Inc. is a commercial-stage medical technology company listed on the Nasdaq Global Select Market under HTFL. It sells cloud-delivered software that turns a coronary computed tomography angiography scan, or CCTA, into a patient-specific three-dimensional model of coronary anatomy. Its algorithms and computational fluid dynamics then add information about stenosis, plaque burden, plaque composition and blood-flow restriction. The practical aim is to help clinicians diagnose and manage coronary artery disease without first sending every patient to invasive angiography.

The company therefore sits at the intersection of medical imaging, artificial intelligence, cardiology workflow and reimbursement. It is not a scanner manufacturer and does not sell implantable devices. Instead, it analyzes imaging data created by existing CT infrastructure. That asset-light delivery model matters: adoption can expand through software integration, physician education and case volume rather than through a large installed base of Heartflow-owned hardware. The company describes its broader objective on its official company overview as making coronary care more proactive, personalized and manageable over a patient’s lifetime.

Where does Heartflow fit in the care pathway?

Heartflow is used after a clinician orders a CCTA. RoadMap helps identify anatomy; FFRCT estimates whether a lesion restricts blood flow; Plaque Analysis quantifies disease burden; and PCI Navigator helps plan revascularization. The platform is intended to support, not replace, professional judgment. Its official indications and safety information also define patient populations and imaging-quality limitations, an important reminder that clinical utility depends on appropriate scans, validated use cases and physician interpretation.

How does Heartflow make money?

Substantially all revenue is usage-driven. An account sends a CCTA to Heartflow and pays when a physician orders and receives FFRCT Analysis, Plaque Analysis or both. Heartflow calls each delivered analysis a “revenue case”; ordering two analyses from one scan counts as two cases. This resembles a transaction model more than a conventional annual software subscription. Revenue therefore depends on the number of active accounts, physician utilization inside those accounts, product mix and the realized price per case.

Which product currently drives the economics?

FFRCT remains overwhelmingly dominant. The FFRCT product description explains how Heartflow combines anatomy with lesion-specific physiology. The concentration creates a clean growth engine but also a major risk: the business is still highly dependent on one product and on continued adoption of the CCTA-plus-Heartflow diagnostic pathway.

What determines revenue per case?

Volume and price do not move identically. In Q1 2026, revenue cases rose 67% year over year while revenue rose 41%. Management attributed the gap partly to a higher mix of clinic and office-based accounts, which generally carry lower pricing than hospital accounts, and to volume rebates. Office and clinic locations generated 36% of U.S. revenue cases in Q1 2026, up from 30% a year earlier. That mix can widen access and expand volume while reducing average selling price, a classic scale-versus-price trade-off.

What does Heartflow’s latest quarter show?

The quarter ended March 31, 2026 showed strong demand and improving production economics, but not operating leverage. Revenue increased to $52.6 million from $37.2 million, gross profit rose 51% to $42.2 million and gross margin expanded to 80.2% from 75.1%. The company said higher case volume and productivity gains from AI efficiency initiatives drove the improvement. This is the most constructive part of the financial story: cost of revenue increased only 13% while revenue increased 41%.

Why did the loss remain large?

Operating expenses climbed to $71.7 million, or 136% of revenue. That included a $7.5 million non-cash facility impairment, but even non-GAAP operating expenses were $57.8 million, or 110% of revenue. Research and development increased 55% to $21.6 million, while selling, general and administrative expense increased 35% to $42.6 million. Heartflow is spending ahead of revenue on sales coverage, clinical research, product development and public-company infrastructure.

Management raised 2026 revenue guidance to $228 million to $232 million, implying approximately 29% to 32% growth over 2025, and guided to about 81% non-GAAP gross margin. The official Q1 2026 earnings release and Form 10-Q provide the full period detail.

Which turning points shaped Heartflow’s strategy?

Heartflow’s current economics are the result of a long regulatory and evidence-building cycle rather than a sudden software launch. The key events are those that expanded clinical credibility, reimbursement, product breadth or financing capacity.

1. 1995–2010
   Image-based coronary blood-flow modeling was developed before Heartflow’s Silicon Valley founding in 2010, creating the scientific base for FFRCT.
2. 2011–2014
   CE marking in 2011 and U.S. FDA clearance in 2014 moved the technology from research into regulated commercial use.
3. 2017–2021
   NICE guidance, Japanese reimbursement and NHS adoption improved institutional legitimacy and international access.
4. 2022
   FDA clearance of Plaque Analysis and RoadMap broadened Heartflow from functional diagnosis toward anatomical characterization and disease management.
5. 2023–2024
   Heartflow One, interactive Plaque Analysis and new reimbursement codes strengthened the platform model and reduced dependence on a single clinical question.
6. 2025
   The Nasdaq IPO raised approximately $332.4 million net, enabled full term-loan repayment and funded commercial and research expansion.
7. 2026–2027
   PCI Navigator launched in April 2026, while Plaque Tracker is planned for 2027, extending the platform from diagnosis into procedure planning and longitudinal monitoring.

What did the IPO change?

The August 2025 IPO converted preferred stock and convertible notes into common equity, issued 19.2 million shares at $19 and produced $332.4 million of net proceeds. Heartflow then repaid $115.1 million of term-loan principal during 2025. The resulting balance sheet is materially less leveraged, but the company also became exposed to public-company costs, quarterly execution pressure and equity dilution from employee compensation.

What gives Heartflow a competitive advantage?

How strong is the evidence-and-data flywheel?

By early 2026, Heartflow reported more than 650,000 patients assessed, more than 1,800 institutions using the platform, more than 625 peer-reviewed publications and over 200 million annotated CCTA images. More cases can improve commercial credibility and create a broader dataset for algorithm development; broader product utility can increase account utilization; higher utilization can create still more data. This is a data flywheel, but its value depends on regulatory discipline, privacy controls and demonstrable clinical performance rather than raw image count alone.

Do patents and workflow create defensibility?

At December 31, 2025, the company reported approximately 617 issued patents and 93 pending applications globally, including claims related to FFRCT, Plaque Analysis and RoadMap. Heartflow’s April 2026 patent suit against Cleerly, described in the company’s official litigation announcement, demonstrates both the perceived value of the portfolio and the cost of defending it. Patents are only one barrier. Integration with hospital systems, reimbursement processes, customer support, physician education and an approximately 12-month ramp for new accounts can create operational switching costs.

How financially strong is Heartflow?

Heartflow’s financial profile is a combination of high gross margin, fast growth, significant operating losses and a post-IPO liquidity cushion. At March 31, 2026, cash, cash equivalents and investments totaled $254.9 million. Stockholders’ equity was $285.7 million, and the company had no term-loan balance after its 2025 repayment. That provides time to fund growth, but it is not the same as self-financing strength because operating cash use was $30.1 million in Q1 2026.

What does the annual baseline show?

For FY2025, revenue increased 40% to $176.0 million and gross margin reached 76.8%, up from 75.1% in FY2024. Revenue case volume increased 47%, but average selling price declined because of customer mix and rebates. Operating loss was $64.1 million. The much larger $116.8 million net loss included non-cash warrant remeasurement and debt-related charges that became less relevant after the IPO and debt repayment. The FY2025 Form 10-K is therefore essential for separating operating performance from financing-accounting noise.

Who owns Heartflow stock, and why does governance matter?

Heartflow has one class of common stock, with one vote per share. That avoids a founder-controlled dual-class structure, but ownership is still concentrated. As of April 24, 2026, four holders each owned more than 5%, and directors and executive officers as a group beneficially owned 7.7%. Large institutional and legacy financing investors can therefore influence voting outcomes, director elections and market liquidity.

How is the board structured?

The 2026 proxy reported seven directors, six of whom the board determined were independent under Nasdaq standards. William Weldon served as independent chair, separate from CEO John Farquhar, and the board was divided into three staggered classes. All audit, compensation, and nominating-and-governance committee members were independent. The 2026 proxy statement also shows that annual bonuses for named executives were paid at 112.2% of target based on 2025 company and individual performance. Investors should watch how future compensation metrics evolve as profitability and cash-flow goals become more important.

Which KPIs best explain Heartflow’s performance?

How should researchers connect the KPIs?

This chain is more informative than revenue alone. A strong quarter would ideally combine rising cases, a narrowing gap between case and revenue growth, higher Plaque Analysis attachment, stable reimbursement, gross-margin expansion and lower cash burn as a percentage of revenue. Heartflow currently has the first and fourth elements; the transition to durable operating leverage remains unfinished.

Who competes with Heartflow, and what could weaken its position?

Heartflow competes against both established diagnostic practice and newer AI platforms. Traditional stress tests such as SPECT, stress echocardiography and PET remain the primary alternatives, supported by large imaging vendors including Siemens Healthineers, GE HealthCare, Philips and Canon Medical. AI-based CCTA competitors named in Heartflow’s 10-K include Cleerly, Elucid Bioimaging and Keya Medical. The competitive question is therefore not simply which algorithm performs best; it is which pathway wins on accuracy, evidence, speed, reimbursement, workflow integration, cost and physician familiarity.

What risks are most material?

The most important strategic tension is that Heartflow must invest heavily to entrench a new standard of care while proving that the model can become profitable. Competition and reimbursement can slow growth; aggressive spending can preserve leadership but extend cash burn. That trade-off should be evaluated quarter by quarter rather than reduced to a generic “AI healthcare growth” narrative.

Why does Heartflow matter for a DCF valuation?

A conventional valuation based on current earnings is not very informative because Heartflow remains loss-making and some historical net-loss volatility came from financing instruments that disappeared after the IPO. A DCF must instead model the operating transition: case growth, realized revenue per case, product attachment, gross margin, sales efficiency, R&D intensity, working capital and the time required to reach positive free cash flow.

Which assumptions have the highest sensitivity?

• Revenue-case growth: the primary volume driver, but it must be translated into revenue after rebates and site mix.
• Plaque Analysis attachment: a key source of incremental revenue and potential shared-scan margin leverage.
• Operating expense discipline: the decisive variable between a high-gross-margin platform and a permanently cash-consuming commercial organization.
• Terminal margin: highly uncertain because the company has not demonstrated steady-state sales, R&D or public-company cost ratios.
• Discount rate and dilution: a recently public, unprofitable medtech company warrants greater uncertainty than a mature profitable software or device company.

What is the key takeaway from Heartflow analysis?